FDA
-
-
-
-
-
-
-
Decibel Therapeutics (DBTX) Receives European Orphan Drug Designation for Lead Gene Therapy Candidate DB-OTO
-
-
-
-
-
-
-
Decibel Therapeutics Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Lead Gene Therapy Candidate DB-OTO
-
-
-
-
-
-
-
Decibel Therapeutics Receives FDA Clearance of IND Application for DB-OTO, a Gene Therapy Product Candidate Designed to Provide Hearing to Individuals with Otoferlin-Related Hearing Loss
-
-
-
-
-
-
-
Decibel Therapeutics Reports First Quarter 2022 Financial Results and Corporate Update
-
-
-
-
-
-
-
Decibel Therapeutics (DBTX) Receives Orphan Drug and Rare Pediatric Disease Designations for DB-OTO for the Treatment of Otoferlin-Related Congenital Hearing Loss
-
-
-
-
-
-
-
Decibel Therapeutics Appoints Dr. William H. Carson as Chairman of the Board of Directors
-
-
-
-
-
-
322,084 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

